Alkermes (ALKS) Current Deferred Revenue (2011 - 2025)
Alkermes' (ALKS) quarterly Current Deferred Revenue came in at $578000.0 in Q2 2025, down 82.54% year-on-year from $3.3 million in Q2 2024, and down 64.08% on a QoQ basis from $1.6 million in Q1 2025.
Alkermes (ALKS) Current Deferred Revenue (2011 - 2025) Analysis & Trends
Alkermes (ALKS) has 15 years of Current Deferred Revenue data on file, last reported at $578000.0 in Q2 2025.
- On a quarterly basis, Current Deferred Revenue fell 82.54% year-over-year to $578000.0 in Q2 2025; TTM through Jun 2025 was $578000.0, a 82.54% decrease from a year earlier, with the FY2024 full-year figure at $1.2 million, down 73.84% from the prior year.
- Current Deferred Revenue for Q2 2025 stood at $578000.0, down from $1.6 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for ALKS reached as high as $22.7 million in Q1 2021 and fell as low as $578000.0 in Q2 2025.
- Historically, Current Deferred Revenue has averaged $7.9 million across 5 years, with a median of $4.7 million in 2023.
- Across the five-year window, Current Deferred Revenue surged 232.39% in 2021 and slumped 82.54% in 2025, its largest moves.
- Year by year, Current Deferred Revenue stood at $17.8 million in 2021, then tumbled by 39.98% to $10.7 million in 2022, then slumped by 55.38% to $4.8 million in 2023, then tumbled by 73.84% to $1.2 million in 2024, then slumped by 53.72% to $578000.0 in 2025.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $578000.0 in Q2 2025, $1.6 million in Q1 2025, and $1.2 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 578,000.00 |
| Mar 31, 2025 | 1.61 Mn |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 4.57 Mn |
| Dec 31, 2023 | 4.78 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | 3.30 Mn |
| Mar 31, 2023 | 6.41 Mn |
| Dec 31, 2022 | 10.70 Mn |
| Sep 30, 2022 | 3.98 Mn |
| Jun 30, 2022 | 13.76 Mn |
| Mar 31, 2022 | 14.85 Mn |
| Dec 31, 2021 | 17.83 Mn |
| Sep 30, 2021 | 6.40 Mn |
| Jun 30, 2021 | 20.80 Mn |
| Mar 31, 2021 | 22.67 Mn |
| Dec 31, 2020 | 23.91 Mn |
| Sep 30, 2020 | 25.79 Mn |